Amyris (AMRS) Given Daily Media Impact Score of 0.19

News stories about Amyris (NASDAQ:AMRS) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amyris earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.7578684168154 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Several research analysts have weighed in on the company. HC Wainwright set a $15.00 price objective on Amyris and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Cowen reissued a “hold” rating and set a $4.00 price objective on shares of Amyris in a report on Wednesday, November 29th. ValuEngine cut Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research raised Amyris from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Amyris presently has a consensus rating of “Hold” and a consensus target price of $20.69.

Amyris (NASDAQ:AMRS) opened at $3.55 on Monday. The company has a market capitalization of $151.91, a P/E ratio of -0.57 and a beta of 0.16. The company has a debt-to-equity ratio of -0.78, a current ratio of 0.92 and a quick ratio of 0.82. Amyris has a one year low of $1.86 and a one year high of $12.45.

Amyris (NASDAQ:AMRS) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.04). The business had revenue of $24.20 million during the quarter, compared to analyst estimates of $36.30 million. During the same period last year, the firm posted ($0.07) earnings per share. The company’s quarterly revenue was down 8.8% on a year-over-year basis. analysts expect that Amyris will post -3.32 earnings per share for the current year.

WARNING: “Amyris (AMRS) Given Daily Media Impact Score of 0.19” was published by Week Herald and is the sole property of of Week Herald. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://weekherald.com/2017/12/25/amyris-amrs-given-daily-media-impact-score-of-0-19.html.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply